NEW YORK, March 17, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of securities of Maravai Lifesciences Holdings, Inc. (NASDAQ: MRVI) between August 7, 2024 and February 24, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 5, 2025.So what: If you purchased Maravai securities during ...

NEW YORK, March 17, 2025 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP announces the filing of a securities class action lawsuit against Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI). This lawsuit, filed on behalf of those who purchased Maravai securities between August 7, 2024, and February 24, 2025, alleges that the company made materially misleading statements and failed to disclose crucial information to investors.The complaint alleges several key issues. Specifically, it claims Maravai ...

NEW YORK, March 17, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI).Shareholders who purchased shares of MRVI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/maravai-lifesciences-holdings-inc-loss-submission-form/?id=136030&fr ...

Core Viewpoint - A class action lawsuit has been filed against Maravai LifeSciences Holdings, Inc. for alleged violations of federal securities laws, particularly concerning inadequate internal controls and improper revenue recognition [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Maravai made false and misleading statements regarding its financial reporting and failed to maintain adequate internal controls [2]. - Allegations include improper revenue recognition from certain transactions in fiscal 2024 and an overstatement of goodwill [2]. Group 2: Investor Information - Shareholders who purchased Maravai's securities between August 7, 2024, and February 24, 2025, are encouraged to contact the DJS Law Group before May 5, 2025, to participate in the lawsuit [1].

Core Viewpoint - A securities class action lawsuit has been filed against Maravai LifeSciences Holdings, Inc. for allegedly making materially false and misleading statements regarding its business operations and financial reporting during the Class Period from August 7, 2024, to February 24, 2025 [1][2]. Allegations Against Defendants - The complaint claims that Maravai lacked adequate internal controls over financial reporting related to revenue recognition [2] - It is alleged that Maravai inaccurately recognized revenue on certain transactions during fiscal 2024 [2] - The lawsuit states that Maravai's goodwill was overstated, leading to misleading positive statements about the company's business and prospects [2] Lead Plaintiff Process - Investors in Maravai have until May 5, 2025, to seek appointment as a lead plaintiff representative of the class [3] - A lead plaintiff acts on behalf of all class members and typically has the largest financial interest in the case [3] - The decision to serve as a lead plaintiff does not affect an investor's ability to share in any recovery [3] Firm Background - Kessler Topaz Meltzer & Check, LLP has a reputation for prosecuting class actions and has recovered billions for victims of corporate misconduct [4] - The firm encourages Maravai investors who have suffered losses to contact them for more information [4]

Core Viewpoint - The stock market is experiencing volatility, leading to concerns about the economy, and while buying stocks during downturns can be beneficial for long-term investors, not all struggling stocks will recover. Group 1: SoundHound AI - SoundHound AI has seen its stock price decline over 55% since the beginning of the year after a significant rise of 836% last year, primarily due to Nvidia selling its stake in the company [3][4] - The company reported a revenue increase of 85% to $84.7 million last year, but also posted an adjusted net loss of $69.1 million, which is 19% higher than the previous year, raising questions about its future growth potential [5] - There are concerns regarding SoundHound's ability to compete in a crowded AI market, which may hinder its organic growth despite its current revenue generation [4][5] Group 2: Maravai LifeSciences - Maravai LifeSciences' stock has also dropped around 55% this year, following a surge in demand for its products during the pandemic, particularly for mRNA vaccine development [6] - The company reported a revenue of $202.8 million for the nine months ending September 30, 2024, which is a 6% decrease year over year, alongside an operating loss of $197.5 million, including significant goodwill impairment charges [7] - With uncertain future profitability and a lack of positive indicators, the stock may continue to decline as the year progresses [8] Group 3: Victoria's Secret & Co. - Victoria's Secret has experienced a 59% decline in stock price so far in 2025, attributed to disappointing earnings and a bleak outlook [9] - The company projects sales for the current fiscal year to be between $6.2 billion and $6.3 billion, indicating minimal growth compared to the previous year, where sales were $6.2 billion, reflecting less than 1% growth [10] - Management's optimistic forecast assumes improving economic conditions, which may not materialize, potentially leading to even lower sales figures if the economic environment does not improve [11][12]

Core Viewpoint - A securities class action lawsuit has been filed against Maravai LifeSciences Holdings, Inc. for allegedly making false and misleading statements regarding its financial reporting and business operations during the specified Class Period from August 7, 2024, to February 24, 2025 [1]. Group 1: Allegations Against Maravai - The complaint alleges that Maravai lacked adequate internal controls over financial reporting related to revenue recognition [3]. - It is claimed that Maravai inaccurately recognized revenue on certain transactions during fiscal 2024 [3]. - The lawsuit also states that Maravai's goodwill was overstated, leading to materially misleading positive statements about the company's business and prospects [3]. Group 2: Legal Process and Participation - Investors in Maravai have until May 5, 2025, to seek appointment as a lead plaintiff representative of the class [4]. - A lead plaintiff is typically the investor or small group of investors with the largest financial interest and who are representative of the proposed class [4]. - The decision to serve as a lead plaintiff does not affect an investor's ability to share in any recovery from the lawsuit [4].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Maravai LifeSciences To Contact Him Directly To Discuss Their Options If purchased or acquired securities in Maravai LifeSciences between August 7, 2024 and February 24, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, March 15, 2025 (GL ...

BENSALEM, Pa., March 13, 2025 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Maravai LifeSciences Holdings, Inc. ("Maravai" or the "Company") (NASDAQ: MRVI).IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI), CONTACT THE LAW OFFICES OF HOWARD G. SMITH BEFORE MAY 5, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LA ...

NEW YORK, March 13, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI).Shareholders who purchased shares of MRVI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/maravai-lifesciences-holdings-inc-loss-submission-form/?id=135500&fr ...